罗格列酮、市场营销与医学科学。 - Suppr

Suppr

超能文献

Rosiglitazone, marketing, and medical science.

作者信息

Moynihan Ray

机构信息

University of Newcastle, Newcastle, Australia.

出版信息

BMJ. 2010 Apr 7;340:c1848. doi: 10.1136/bmj.c1848.

DOI:10.1136/bmj.c1848

PMID:20375091

Abstract

摘要

相似文献

Rosiglitazone, marketing, and medical science.

BMJ. 2010 Apr 7;340:c1848. doi: 10.1136/bmj.c1848.

Rosiglitazone: what went wrong?

BMJ. 2010 Sep 6;341:c4848. doi: 10.1136/bmj.c4848.

The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.

N Engl J Med. 2013 Oct 3;369(14):1285-7. doi: 10.1056/NEJMp1309610. Epub 2013 Sep 2.

FDA puts rosiglitazone post-marketing trial on hold.

BMJ. 2010 Jul 26;341:c4017. doi: 10.1136/bmj.c4017.

Rosiglitazone: failure of oversight or demons imagined?

J Fam Pract. 2007 Sep;56(9):696, 703.

The painful truth.

Eur Heart J. 2010 May;31(10):1284-5. doi: 10.1093/eurheartj/ehq126. Epub 2010 Apr 23.

The rosiglitazone meta-analysis.

Rev Cardiovasc Med. 2007 Spring;8(2):123-6.

Diabetes drug safety update: Avandia and your heart.

Johns Hopkins Med Lett Health After 50. 2010 Jun;22(4):1-2, 7.

Rosiglitazone and implications for pharmacovigilance.

BMJ. 2007 Jun 16;334(7606):1233-4. doi: 10.1136/bmj.39245.502546.BE.

Revisiting the rosiglitazone story--lessons learned.

N Engl J Med. 2010 Aug 26;363(9):803-6. doi: 10.1056/NEJMp1008233. Epub 2010 Jul 21.

引用本文的文献

Criminals in the Citadel and Deceit all along the Watchtower: Irresponsibility, Fraud, and Complicity in the Search for Scientific Truth.

Mens Sana Monogr. 2012 Jan;10(1):158-80. doi: 10.4103/0973-1229.91426.

Physiotherapy trials for the 21st century: time to raise the bar?

J R Soc Med. 2011 Nov;104(11):437-41. doi: 10.1258/jrsm.2011.110109.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Rosiglitazone, marketing, and medical science.

BMJ. 2010 Apr 7;340:c1848. doi: 10.1136/bmj.c1848.

Rosiglitazone: what went wrong?

BMJ. 2010 Sep 6;341:c4848. doi: 10.1136/bmj.c4848.

The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.

N Engl J Med. 2013 Oct 3;369(14):1285-7. doi: 10.1056/NEJMp1309610. Epub 2013 Sep 2.

FDA puts rosiglitazone post-marketing trial on hold.

BMJ. 2010 Jul 26;341:c4017. doi: 10.1136/bmj.c4017.

Rosiglitazone: failure of oversight or demons imagined?

J Fam Pract. 2007 Sep;56(9):696, 703.

The painful truth.

Eur Heart J. 2010 May;31(10):1284-5. doi: 10.1093/eurheartj/ehq126. Epub 2010 Apr 23.

The rosiglitazone meta-analysis.

Rev Cardiovasc Med. 2007 Spring;8(2):123-6.

Diabetes drug safety update: Avandia and your heart.

Johns Hopkins Med Lett Health After 50. 2010 Jun;22(4):1-2, 7.

Rosiglitazone and implications for pharmacovigilance.

BMJ. 2007 Jun 16;334(7606):1233-4. doi: 10.1136/bmj.39245.502546.BE.

Revisiting the rosiglitazone story--lessons learned.

N Engl J Med. 2010 Aug 26;363(9):803-6. doi: 10.1056/NEJMp1008233. Epub 2010 Jul 21.

引用本文的文献

Criminals in the Citadel and Deceit all along the Watchtower: Irresponsibility, Fraud, and Complicity in the Search for Scientific Truth.

Mens Sana Monogr. 2012 Jan;10(1):158-80. doi: 10.4103/0973-1229.91426.

Physiotherapy trials for the 21st century: time to raise the bar?

J R Soc Med. 2011 Nov;104(11):437-41. doi: 10.1258/jrsm.2011.110109.